CAP Statement on the Introduction of the Verified Innovative Testing in American Laboratories Act of 2020
WASHINGTON--(BUSINESS WIRE)-- College of American Pathologists (CAP) President Patrick Godbey, MD, FCAP issued the following statement after the release of the Verified Innovative Testing in American Laboratories Act of 2020 on March 18:
“The CAP opposes the Verified Innovative Testing in American Laboratories Act of 2020 and any disruptive effort to redefine laboratory-developed tests during this national emergency. Presently, our efforts are focused on leveraging existing structures and streamlining processes to ensure increasing patient access to tests while maintaining necessary safeguards. The CAP looks forward to engaging further with stakeholders on the oversight of laboratory-developed tests once we have moved past the COVID-19 pandemic.”
About the College of American Pathologists
As the world’s largest organization of board-certified pathologists and leading provider of laboratory accreditation and proficiency testing programs, the College of American Pathologists (CAP) serves patients, pathologists, and the public by fostering and advocating excellence in the practice of pathology and laboratory medicine worldwide. As a 501(c)(6) membership organization, the CAP is the only entity representing pathologists with unrestricted advocacy capability and a political action committee, PathPAC. For more information, visit yourpathologist.org to watch pathologists at work and see the stories of the patients who trust them with their care. Read the CAP Annual Report at cap.org.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200318005788/en/
Source: College of American Pathologists
View this news release online at: